It was the first news of EMA's probe of the J&J vaccine, while AstraZeneca's coronavirus vaccine has been dogged for weeks over possible links to rare blood clots.
Dr. Howard Njoo, Canada's deputy chief public health officer, suggested more guidance could be coming for people under age 55 who received the AstraZeneca vaccine.
The EMA, the World Health Organization and numerous other health authorities have said repeatedly that the AstraZeneca vaccine is safe and effective.
The trial disruption is the latest blow to the AstraZeneca vaccine, once hailed as a milestone in the fight against the COVID-19 pandemic.
The regulator has consistently said the benefits outweigh the risks as it investigates 44 reports of an extremely rare brain clotting ailment.
Concerns over the AstraZeneca vaccine prompted some countries including Canada, France, Germany and the Netherlands to restrict its use to older people.
A 44-year-old man was admitted to a Melbourne hospital with clotting days after receiving the AstraZeneca vaccine, suffering serious thrombosis.
Australian media reported that a 44-year-old man was admitted to a Melbourne hospital with possible clotting days after receiving the COVID-19 vaccine.
The health officials said they still believe the benefits of the vaccine in the prevention of COVID-19 far outweigh any possible risk of blood clots.
The agency says it continues to study reports of new cases as they come in and will provide a further assessment next week.
While the impact might not reach Canada, it could have far-reaching implications for other nations.
Under a less stringent export control system in force so far, only one shipment in 381 has been barred from leaving the EU.
Coupled with earlier missteps in reporting data and a recent blood clot scare, experts said the new stumble could cause lasting harm to the shot that is key to global efforts.
AstraZeneca's shot, for example, is being produced in various locations including South Korea's SKBioScience and the Serum Institute of India.
Brussels pointed an accusing finger at drugmaker AstraZeneca, claiming the company has been "over-selling its production capacity."
AstraZeneca said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare blood clots identified in Europe.
The end of suspensions will kick off a test of public confidence, both in the shot and in drug regulators whose conclusions are under unprecedented scrutiny.
The Serum Institute of India said it had delivered 5 million doses to Britain a few weeks ago but that there was no contract period stipulated for delivery.
The Biden administration has come under pressure from allies worldwide to share vaccine, particularly from AstraZeneca.
Figures from the European Centers for Disease Prevention and Control this week show there are about 7 million unused AstraZeneca vaccines across the 27-nation EU.